About Us

We're here to transform the lives of people affected by neuromuscular disease.

Press Releases

  • Five Questions with DMD Researcher James Ervasti

    James Ervasti, professor in the department of biochemistry, molecular biology & biophysics at the University of Minnesota in Minneapolis, is working to develop methods of identifying non-invasive biomarkers that can be measured in all patients across the entire spectrum of Duchenne muscular dystrophy (DMD) disease severity.

    Please describe your current research in DMD.

  • Supreme Court Upholds Nationwide Health Care Law Subsidies in ACA Ruling

    Background: On June 25th, 2015 the United States Supreme Court ruled to uphold nationwide health care law subsidies. Under the Affordable Care Act (ACA), states were tasked with setting up their own exchanges where individuals could purchase healthcare. Some states created exchanges, while others opted to use exchanges run by the federal government. The question at issue in the Supreme Court case King v.

  • MDA Mourns the Loss of Former National Goodwill Ambassador Mike Neufeldt

    Today the Muscular Dystrophy Association (MDA) mourns the loss of Mike Neufeldt, 37, of New Berlin, Wis. — a voluntary leader, ambassador and beloved member of the MDA family who had a tremendous positive impact on MDA’s mission to save and improve the lives of those fighting neuromuscular diseases, including the Emery-Dreifuss muscular dystrophy Neufeldt battled since childhood.

  • Catalyst Pharmaceuticals Conducting Trial to Test Amifampridine Phosphate (FIRDAPSE®) in Children with Congenital Myasthenic Syndromes

    Statement from Catalyst: Amifampridine phosphate in CMS Clinical Trial

    Researchers are looking for children, ages 2 to 17 years, with congenital myasthenic syndrome (CMS) to participate in a new phase 3 study being conducted by Catalyst Pharmaceuticals to test the experimental drug amifampridine phosphate.

  • MDA Team Momentum Fights Back Against Neuromuscular Disease at the 2015 Marine Corps Marathon

    WASHINGTON, D.C., Oct. 20, 2015 — The Muscular Dystrophy Association’s nationwide endurance program MDA Team Momentum will make its second appearance at the 2015 Marine Corps Marathon on Oct. 25 to help support MDA’s mission to save and improve the lives of kids and adults fighting muscular dystrophy, ALS and related life-threatening diseases that severely limit muscle strength and mobility.

  • Enrollment in Diaphragm Pacing Systems for People with ALS Halted

    In September, the Data Safety and Monitoring Board (DSMB), constituted to oversee the Diaphragm Pacing System in Participants with Amyotrophic Lateral Sclerosis (DPS in ALS) study, being conducted in the United States, issued a recommendation that new enrollment be halted. At the same time, the DSMB recommended that patients already randomized to the diaphragm pacing arm continue to be actively stimulated and followed according to the protocol.